Resource Type

Journal Article 3

Year

2022 1

2021 1

2015 1

Keywords

Akkermansia muciniphila 1

Dietary restriction 1

HCV core protein 1

Hepatocellular carcinoma 1

NAFLD 1

NASH 1

Saturated fatty acid 1

Steatosis 1

Trans fatty acid 1

diabetes 1

hepatic steatosis 1

inflammation 1

inflammatory response 1

insulin resistance 1

metformin 1

steatosis 1

open ︾

Search scope:

排序： Display mode:

Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 667-685 doi: 10.1007/s11684-022-0960-z

Abstract: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and a common cause of liver cirrhosis and cancer. Akkermansia muciniphila (A. muciniphila) is a next-generation probiotic that has been reported to improve metabolic disorders. Emerging evidence indicates the therapeutic potential of A. muciniphila for NAFLD, especially in the inflammatory stage, nonalcoholic steatohepatitis. Here, the current knowledge on the role of A. muciniphila in the progression of NAFLD was summarized. A. muciniphila abundancy is decreased in animals and humans with NAFLD. The recovery of A. muciniphila presented benefits in preventing hepatic fat accumulation and inflammation in NAFLD. The details of how microbes regulate hepatic immunity and lipid accumulation in NAFLD were further discussed. The modulation mechanisms by which A. muciniphila acts to improve hepatic inflammation are mainly attributed to the alleviation of inflammatory cytokines and LPS signals and the downregulation of microbiota-related innate immune cells (such as macrophages). This review provides insights into the roles of A. muciniphila in NAFLD, thereby providing a blueprint to facilitate clinical therapeutic applications.

Keywords： Akkermansia muciniphila     NAFLD     NASH     steatosis     inflammation    

HTML PDF Collect

Metformin and metabolic diseases: a focus on hepatic aspects

Juan Zheng,Shih-Lung Woo,Xiang Hu,Rachel Botchlett,Lulu Chen,Yuqing Huo,Chaodong Wu

Frontiers of Medicine 2015, Volume 9, Issue 2,   Pages 173-186 doi: 10.1007/s11684-015-0384-0

Abstract: As supported by the results from both human and animal studies, metformin improves hepatic steatosis

Keywords： metformin     diabetes     hepatic steatosis     inflammatory response     insulin resistance    

HTML PDF Collect

Mechanisms of Steatosis-Derived Hepatocarcinogenesis: Lessons from HCV Core Gene Transgenic Mice Review

Pan Diao, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Takero Nakajima, Toshifumi Aoyama, Kyoji Moriya, Kazuhiko Koike, Naoki Tanaka

Engineering 2021, Volume 7, Issue 12,   Pages 1797-1805 doi: 10.1016/j.eng.2021.08.019

Abstract: Transgenic mice carrying the HCV core gene exhibited age-dependent insulin resistance, hepatic steatosisand the microenvironment, thereby corroborating a close interconnection between dietary habits and steatosis-relatedsteatogenesis and hepatocarcinogenesis induced by the HCV core protein and the impact of dietary habits on steatosis-derived

Keywords： Steatosis     Hepatocellular carcinoma     Trans fatty acid     Saturated fatty acid     Dietary restriction     HCV    

HTML PDF Collect

Title Author Date Type Operation

Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives

Journal Article

Metformin and metabolic diseases: a focus on hepatic aspects

Juan Zheng,Shih-Lung Woo,Xiang Hu,Rachel Botchlett,Lulu Chen,Yuqing Huo,Chaodong Wu

Journal Article

Mechanisms of Steatosis-Derived Hepatocarcinogenesis: Lessons from HCV Core Gene Transgenic Mice

Pan Diao, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Takero Nakajima, Toshifumi Aoyama, Kyoji Moriya, Kazuhiko Koike, Naoki Tanaka

Journal Article